Business Description
Xenon Pharmaceuticals Inc
NAICS : 325412
SIC : 3741
ISIN : CA98420N1050
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 66.83 | |||||
Equity-to-Asset | 0.95 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.04 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -57.2 | |||||
3-Year EPS without NRI Growth Rate | -50.2 | |||||
3-Year FCF Growth Rate | -15.4 | |||||
3-Year Book Growth Rate | 38.1 | |||||
Future 3-5Y EPS without NRI Growth Rate | -12.85 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 30.51 | |||||
9-Day RSI | 37.29 | |||||
14-Day RSI | 41.46 | |||||
6-1 Month Momentum % | 8.88 | |||||
12-1 Month Momentum % | -3.66 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 22.21 | |||||
Quick Ratio | 22.21 | |||||
Cash Ratio | 22.02 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -29.1 | |||||
Shareholder Yield % | 0.03 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -26.06 | |||||
ROA % | -24.96 | |||||
ROIC % | -122.26 | |||||
ROC (Joel Greenblatt) % | -1359.32 | |||||
ROCE % | -30.86 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 3.65 | |||||
Price-to-Tangible-Book | 3.65 | |||||
EV-to-EBIT | -8.86 | |||||
EV-to-EBITDA | -8.96 | |||||
EV-to-Forward-Revenue | 905.42 | |||||
EV-to-FCF | -14.24 | |||||
Price-to-Net-Current-Asset-Value | 4.69 | |||||
Price-to-Net-Cash | 4.73 | |||||
Earnings Yield (Greenblatt) % | -11.29 | |||||
FCF Yield % | -5.43 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Xenon Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -2.584 | ||
Beta | 0.57 | ||
Volatility % | 46.18 | ||
14-Day RSI | 41.46 | ||
14-Day ATR (€) | 0.829244 | ||
20-Day SMA (€) | 39.53 | ||
12-1 Month Momentum % | -3.66 | ||
52-Week Range (€) | 33.4 - 46.6 | ||
Shares Outstanding (Mil) | 76.24 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Xenon Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Xenon Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Xenon Pharmaceuticals Inc Frequently Asked Questions
What is Xenon Pharmaceuticals Inc(FRA:XP0)'s stock price today?
When is next earnings date of Xenon Pharmaceuticals Inc(FRA:XP0)?
Does Xenon Pharmaceuticals Inc(FRA:XP0) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |